Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.
Earnings per share fell 946.67% year over year to ($1.57), which missed the estimate of ($0.75).
Revenue of $1,667,000 less by 25.65% year over year, which missed the estimate of $1,750,000.
DarioHealth hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 12, 2020
Time: 08:04 PM ET
Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/34665
Company's 52-week high was at $11.25
52-week low: $0.20
Price action over last quarter: Up 109.21%
DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.